Menu Search
Equities

Masimo Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0JZ2:LSE

Masimo Corp

Actions
  • Price (USD)135.60
  • Today's Change-0.71 / -0.52%
  • Shares traded10.00
  • 1 Year change-24.64%
  • Beta1.2656
Data delayed at least 20 minutes, as of Feb 10 2026 14:44 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.

  • Revenue in USD (TTM)1.72bn
  • Net income in USD-203.80m
  • Incorporated1996
  • Employees3.60k
  • Location
    Masimo Corp52 DiscoveryIRVINE 92618United StatesUSA
  • Phone+1 (949) 297-7000
  • Fax+1 (949) 297-7499
  • Websitehttps://www.masimo.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.